{"prompt": "['Trelagliptin-4002', 'Page 63 of 66', 'Version 2.0', 'July 5, 2017', 'consent form and information sheet is revised. The date of obtaining new consent shall be recorded', \"in the study subject's medical record, and a copy of the revised consent form shall be provided to the\", 'study subject.', '15.4', 'Personal information of the study subjects', \"The sponsor or the designee shall affirm the principle of the protection of study subjects'\", 'private/personal information. Throughout this study, study subject ID codes shall be used to link the', \"subject's source data to the sponsor's study database and study-related documents. Limited\", 'information on study subjects such as gender, age, and date of birth may be used within the scope of', 'all applicable laws and regulations for identification of study subjects and confirmation of accuracy', 'of study subject ID code.', 'For verification of the conduct of the study in compliance with this protocol and the Ethical', 'Guidelines for Medical and Health Research Involving Human Subjects, the sponsor shall require', \"the principal investigator to provide the study sponsor's designee, representatives of regulatory\", 'authorities, designated auditors, and committees such as the Ethical Review Board direct access to', \"study subjects' original medical records (source data or documents), including laboratory test results,\", \"admission and discharge records during a subject's study participation, and autopsy reports. The\", 'principal investigator or investigator shall obtain specific authorization of the study subject as part of', \"the informed consent process for access to study subject's original medical records by study\", \"sponsor's designee and representatives of regulatory authorities (see Section 15.3).\", 'When providing a copy of source documents to the sponsor, the principal investigator or investigator', 'shall delete information that may lead to identification of an individual (name and address of study', 'subject, other personal information not recorded on the CRF of the study subject).', '15.5', 'Consultation windows for the study subjects or persons related to the study', 'concerned', 'The principal investigator shall establish a contact service to respond to inquiries concerning this', 'clinical study from study subjects or concerned people. Details of the contacts for inquiries will be', 'described in the informed consent form and information sheet.', '15.6 Financial burden or reward to the study subjects', 'Of the expenses for this clinical study, the sponsor shall offer compensation for medical treatment', 'not covered by health insurance as study expenses. The study subjects shall pay expenses for', 'medical treatment covered by ordinary health insurance.', 'In addition, the principal investigator shall pay expenses such as transportation expenses for', 'participation in this clinical study to the study subjects at each visit from the research funds. Details', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 64 of 66', 'Version 2.0', 'July 5,10', 'of the financial burden on the study subjects and rewards shall be described in the informed consent', 'form and information sheet.', '15.7', 'Benefits and inconveniences to the study subjects', '15.7.1 Benefits to study subjects', 'Study subjects can deeply learn their own conditions of type 2 diabetes including such as the change', 'in the QOL associated with the change in treatment approaches and the level of treatment', 'satisfaction, through the study participation', '15.7.2 Inconveniences to study subjects', 'Burdens of study subjects may be increased due to requirements of providing answers to the Basic', 'Information on Study Subject, DTR-QOL Questionnaire and DTSQ, through the study participation.', '15.8', 'Attribution of study results and access rights', '15.8.1 Attribution of study results', 'The study results and data obtained from this study shall belong to the sponsor. In addition,', 'secondary use (meta-analysis, etc.) of the data obtained in this clinical study may be possible if used', 'in such a way that the data shall not be linked to personal identification information.', '15.8.2 Data access rights', 'Access rights for all data and information generated from this study will be given to personnel', 'approved by the sponsor.', '15.9', 'Reporting of results, publication, disclosure, and clinical study registration', 'policy', '15.9.1 Reporting of results, publication and disclosure', 'The principal investigator shall report a written summary of results of the study to the chief', 'executive of the study site and provide the sponsor with all the results and data obtained from the', 'study. Only the sponsor may disclose the study information to other principal investigators,', 'investigators or regulatory authorities during the study period, except when required by laws and', 'regulations. The sponsor shall be responsible for publication of the study protocol and study-related', 'results (including the public web site) except for other cases permitted in the study contract.', 'During the study period and after the end of study, the sponsor or the designee should promptly', 'summarize the results and present it to medical journals and academic conferences, etc. The sponsor', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}